The Trump administration’s decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number of questions from physicians.

Defense Secretary Pete Hegseth says the initiative is intended to improve military readiness, resilience, longevity and performance. But many endocrinologists, urologists and men’s health specialists say they have yet to see the scientific evidence supporting universal screening of healthy service members, particularly those without symptoms of testosterone deficiency.

The debate is not about whether testosterone matters. It does. The question is whether a broad federal screening program is supported by sufficient medical evidence to justify its costs, potential risks and downstream consequences.

A Significant Policy Shift

The military’s announcement did not occur in isolation. Over the past year, the federal government’s approach to testosterone has undergone a noticeable evolution.

The U.S. Food and Drug Administration revisited longstanding questions surrounding testosterone regulation, labeling and prescribing, signaling a more permissive regulatory posture than in previous years.

We have followed those developments closely, documenting the growing debate surrounding the FDA’s changing approach to testosterone policy, including concerns raised during advisory committee discussions and subsequent regulatory changes.

While no public evidence demonstrates that the FDA’s actions and the Defense Department’s screening initiative were coordinated, together they represent a significant shift in how the federal government is approaching testosterone testing and treatment.

That chronology naturally raises an important question. Why has federal policy on testosterone changed so dramatically in such a short period of time?

Where Is the Evidence?

Perhaps the most striking aspect of a Reuters report is not that experts disagree with the policy. Rather, many say they do not understand the scientific rationale behind it.

Five of six men’s health experts interviewed questioned the need for universal screening beginning at age 30, noting there is little evidence demonstrating that testing every service member would improve military readiness or combat effectiveness.

The administration has explained its objective of improving readiness but has publicly offered few details explaining why universal screening is necessary, why age 30 was selected, what scientific studies support the policy, and how success will be measured. And, perhaps most importantly, why existing medical guidelines are insufficient.

These are not political questions. They are the questions routinely asked whenever governments introduce large-scale public health initiatives.

Screening Is Not the Same as Diagnosis

Medical organizations such as the American Urological Association and the Endocrine Society recommend testosterone replacement only when patients have both documented testosterone deficiency and corresponding clinical symptoms, including fatigue, reduced libido, erectile dysfunction, decreased muscle mass or low bone density.

Universal screening changes that equation. Rather than identifying patients seeking care for symptoms, it tests an entire population, including individuals who may feel perfectly healthy.

That distinction matters. One of the fundamental principles of preventive medicine is that screening programs should demonstrate that the condition is sufficiently common, early detection improves outcomes, and the benefits outweigh potential harms.

Several physicians interviewed by Reuters questioned whether that standard has been established for universal testosterone screening in otherwise healthy military personnel.

The Screening Cascade

A testosterone test is not simply a blood draw. Abnormal results frequently trigger additional laboratory testing, physician evaluations, specialist referrals, repeat measurements and, in some cases, testosterone replacement therapy itself.

Experts interviewed by Reuters warned that inappropriate prescribing may expose patients to significant risks, including infertility, testicular shrinkage, blood thickening, abnormal heart rhythms, prostate complications, acne, hair loss and mood changes.

Those concerns become particularly relevant in a military population composed largely of younger adults, many of whom have not yet started or completed their families.

Readiness May Depend on More Than Hormones

Hegseth cited “Operator Syndrome” as one reason for expanding screening. That syndrome has been described among certain elite Special Operations personnel exposed to repeated blast injuries, sleep disruption and extreme operational stress.

But researchers familiar with the condition caution that these highly specialized operators are not representative of the broader military population. One researcher told Reuters that whether every service member should be screened remains an open question.

Other experts noted that poor sleep, inadequate recovery, obesity, nutrition and chronic stress can all lower testosterone levels, and that addressing those underlying factors may restore hormone levels without medication.

Interestingly, research discussed in a recent Washington Post opinion article notes that some of the military’s most demanding training environments can temporarily reduce testosterone levels substantially because of sleep deprivation, calorie deficits and prolonged physical stress. The authors argue that fluctuating testosterone is often a normal physiological response rather than evidence of disease.

Follow the Policy, and the Procurement

The administration’s decision also creates practical questions beyond medicine.

A nationwide screening initiative has implications for laboratory testing, physician visits, follow-up care, prescription medications, long-term monitoring and procurement contracts throughout the military healthcare system.

Those realities do not imply wrongdoing. They do, however, underscore why transparency matters.

Congress, taxpayers and service members deserve to know what evidence justified the program, what outcomes are expected, what will the program cost, how will contracts be awarded, and how will success be measured.

Those questions should accompany any major federal healthcare initiative.

Our Take

Major changes in public health policy deserve major explanations.

If universal testosterone screening will truly improve military readiness, the administration should be able to present the scientific evidence supporting that conclusion, explain why existing medical guidelines are insufficient, identify the expected benefits, acknowledge the potential risks and disclose the anticipated costs.

That level of transparency should not be viewed as political. It is the foundation of evidence-based medicine and good government.

Until those questions are answered, the debate over testosterone screening is likely to remain focused less on hormone levels than on the evidence, and reasoning, that led the federal government to make such a significant policy shift.